Health Care • Biotechnology: Electromedical & Electrotherapeutic Apparatus
$96.54 ▼ -0.57
(-0.59%)
MKT CAP: $123.49B • VOL: 8.68M
52W L $73 52W H $106
MDT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2026-04-24 | FY 2024
FILED 2025-04-25 | FY 2023
FILED 2024-04-26 |
|---|---|---|---|
| Revenue (Total Sales) | $36.36B | $33.54B | $32.36B |
| YoY Revenue Growth % | +8.4% | +3.6% | — |
| Gross Profit | $23.64B | $21.91B | — |
| Gross Margin % | 65.0% | 65.3% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $6.47B | $5.96B | $5.14B |
| Operating Margin % | 17.8% | 17.8% | 15.9% |
| Net Income (GAAP) | $4.8K | $4.7K | $3.7K |
| EBITDA (Normalized) | $7.99B | $7.44B | $6.31B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $7.33B | $7.04B | $6.79B |
| Capital Expenditures (CapEx) | $1.90B | $1.86B | $1.46B |
| Free Cash Flow (FCF) | $5.43B | $5.18B | $5.33B |
| FCF Margin % | 14.9% | 15.5% | 16.5% |
| Return on Invested Capital (ROIC %) | 7.6% | 7.1% | 9.8% |
| Cash & Short-Term Equivalents | $1.15B | $1.24B | — |
| Total Debt (Short + Long Term) | $19.03B | $18.16B | $15.99B |
| Total Stockholders' Equity | $48.98B | $49.39B | $32.79B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR MDT.